PR Newswire10.31.17
Arthrosurface Inc. announced that it has completed the acquisition of an acellular dermal stabilization device technology, including the intellectual property rights to and associated with this technology, from WASAS, LLC based in Fort Lauderdale, Fla. Arthrosurface plans to use this technology to develop and market a platform of novel methods to be used to correct orthopedic challenges in multiple therapeutic areas.
Acellular dermis is derived from a human source, a process is used to remove cells and retain portions of the extracellular matrix (ECM). Dermal allografts have a history of human use in a wide range of clinical indications.
"The availability of this allograft to Arthrosurface will allow us to execute on a pipeline of clinical applications that we have identified with our surgeon partners over the past several years," said Steve Ek, CEO of Arthrosurface.
Acellular dermis is derived from a human source, a process is used to remove cells and retain portions of the extracellular matrix (ECM). Dermal allografts have a history of human use in a wide range of clinical indications.
"The availability of this allograft to Arthrosurface will allow us to execute on a pipeline of clinical applications that we have identified with our surgeon partners over the past several years," said Steve Ek, CEO of Arthrosurface.